Researcher notes study closely simulates real patient motion
using human subjects
PLEASANTON, Calif., Oct. 17 /PRNewswire/ -- The Nellcor Oximetry Business
of Mallinckrodt Inc. (NYSE: MKG) today announced that the Nellcor(R) N-395
with Oxismart(R) XL and Sat Seconds(TM) technology outperformed five other
monitors during motion, according to the results of two separate studies
presented Monday morning at the American Society of Anesthesiologists
conference in San Francisco.
Separate studies led by Hartmut Gehring, MD, of the Department of
Anesthesiology at Medical University Luebeck, Luebeck, Germany, and Michael W.
Jopling, MD, of the Anesthesiology Department at St. Ann's Hospital Columbus,
Ohio, compared Nellcor N-395 monitors against other brands of pulse oximetry
equipment. In each case, the N-395 oximeters fared best.
Dr. Gehring's study, entitled Artifact Resistance of Newest Generation of
Pulse Oximeters in Volunteers Undergoing Hypoxemia, tested oximetry
performance in healthy adult volunteers during motion combined with simulated
low perfusion. Five different pulse oximeters from four manufactures were
tested, including Nellcor N-395 and N-3000 monitors, a Datex-Ohmeda 3900, an
Agilent CMS Rev. B.0., and a Schiller OX-1, the European version of the Ivy
2000/Masimo SET(R). The research was co-sponsored by Agilent, Datex-Ohmeda and
Mallinckrodt.
"Combining performance with respect to SpO2 accuracy, pulse rate accuracy
and alarm handling, the Nellcor N-395 demonstrated superior performance in
comparison with other new generation pulse oximeters," concluded Dr. Gehring
and his investigative team.
Dr. Jopling's study investigated the effects of motion artifact on the
alarm performance of the Nellcor N-395/Oxismart(R) XL, Ivy 2000/Masimo SET and
the older technology Nellcor NPB-290/Oxismart. "During severe motion artifact,
the N-395/Oxismart(R) XL exhibited superior performance," concluded Dr.
Jopling and co-investigators in their study, Sensitivity and Specificity
Performance During Motion Artifact in Three Pulse Oximeters Designed for Use
in Motion.
During the more challenging motion conditions, the N-395 detected 30 of 32
hypoxemic events, while the Ivy 2000 and NPB-290 only detected 26 and 19
events, respectively. The N-395 also reported significantly fewer false
alarms.
"As Dr. Jopling pointed out in the question and answer session, his study
tests oximetry performance on human subjects that are simulating real chaotic
patient motion. Other oximetry studies use rhythmic motion machines or pulse-
simulating machines," said Doris Engibous, vice president and general manager,
Nellcor Oximetry Business. "Both the Luebeck and Jopling studies provide a
valuable tool for clinicians to understand how different oximetry technologies
may perform in challenging clinical situations."
About Mallinckrodt
The Nellcor Oximetry Business of Mallinckrodt is the world leader in pulse
oximetry with over 80 OEM and Licensing partners, 16 sensor choices, over 50
corporate account and IHN purchasing contracts, and four generations of pulse
oximetry technology. Mallinckrodt Inc. is a global manufacturer and marketer
of specialty medical products designed to sustain breathing, diagnose disease
and relieve pain. Named one of America's most admired medical products and
equipment companies by Fortune magazine, Mallinckrodt does business in more
than 100 countries. In fiscal 2000, combined net sales were $2.7 billion for
Mallinckrodt's respiratory, imaging and pharmaceutical product lines. Based in
St. Louis, Missouri, Mallinckrodt's website address is
http://www.mallinckrodt.com.
SOURCE Mallinckrodt Inc.
 back to top
Related links:
http://www.mallinckrodt.com
CONTACT:
Barbara Abbett of Mallinckrodt Inc.,
314-654-5230, barbara.abbett@mkg.com, or Joyce McMahon, ext.
8949, joyce.mcmahon@mullen.com, or Kara Nadeau, ext. 8944,
knadeau@mullen.com, both of Mullen, 978-468-1155
|
